<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="" xml:lang="">
<head>
  <meta charset="utf-8" />
  <meta name="generator" content="pandoc" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0, user-scalable=yes" />
  <title>NURS.V</title>
  <style>
    /* Default styles provided by pandoc.
    ** See https://pandoc.org/MANUAL.html#variables-for-html for config info.
    */
    html {
      color: #1a1a1a;
      background-color: #fdfdfd;
    }
    body {
      margin: 0 auto;
      max-width: 36em;
      padding-left: 50px;
      padding-right: 50px;
      padding-top: 50px;
      padding-bottom: 50px;
      hyphens: auto;
      overflow-wrap: break-word;
      text-rendering: optimizeLegibility;
      font-kerning: normal;
    }
    @media (max-width: 600px) {
      body {
        font-size: 0.9em;
        padding: 12px;
      }
      h1 {
        font-size: 1.8em;
      }
    }
    @media print {
      html {
        background-color: white;
      }
      body {
        background-color: transparent;
        color: black;
        font-size: 12pt;
      }
      p, h2, h3 {
        orphans: 3;
        widows: 3;
      }
      h2, h3, h4 {
        page-break-after: avoid;
      }
    }
    p {
      margin: 1em 0;
    }
    a {
      color: #1a1a1a;
    }
    a:visited {
      color: #1a1a1a;
    }
    img {
      max-width: 100%;
    }
    svg {
      height: auto;
      max-width: 100%;
    }
    h1, h2, h3, h4, h5, h6 {
      margin-top: 1.4em;
    }
    h5, h6 {
      font-size: 1em;
      font-style: italic;
    }
    h6 {
      font-weight: normal;
    }
    ol, ul {
      padding-left: 1.7em;
      margin-top: 1em;
    }
    li > ol, li > ul {
      margin-top: 0;
    }
    blockquote {
      margin: 1em 0 1em 1.7em;
      padding-left: 1em;
      border-left: 2px solid #e6e6e6;
      color: #606060;
    }
    code {
      font-family: Menlo, Monaco, Consolas, 'Lucida Console', monospace;
      font-size: 85%;
      margin: 0;
      hyphens: manual;
    }
    pre {
      margin: 1em 0;
      overflow: auto;
    }
    pre code {
      padding: 0;
      overflow: visible;
      overflow-wrap: normal;
    }
    .sourceCode {
     background-color: transparent;
     overflow: visible;
    }
    hr {
      border: none;
      border-top: 1px solid #1a1a1a;
      height: 1px;
      margin: 1em 0;
    }
    table {
      margin: 1em 0;
      border-collapse: collapse;
      width: 100%;
      overflow-x: auto;
      display: block;
      font-variant-numeric: lining-nums tabular-nums;
    }
    table caption {
      margin-bottom: 0.75em;
    }
    tbody {
      margin-top: 0.5em;
      border-top: 1px solid #1a1a1a;
      border-bottom: 1px solid #1a1a1a;
    }
    th {
      border-top: 1px solid #1a1a1a;
      padding: 0.25em 0.5em 0.25em 0.5em;
    }
    td {
      padding: 0.125em 0.5em 0.25em 0.5em;
    }
    header {
      margin-bottom: 4em;
      text-align: center;
    }
    #TOC li {
      list-style: none;
    }
    #TOC ul {
      padding-left: 1.3em;
    }
    #TOC > ul {
      padding-left: 0;
    }
    #TOC a:not(:hover) {
      text-decoration: none;
    }
    code{white-space: pre-wrap;}
    span.smallcaps{font-variant: small-caps;}
    div.columns{display: flex; gap: min(4vw, 1.5em);}
    div.column{flex: auto; overflow-x: auto;}
    div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
    /* The extra [class] is a hack that increases specificity enough to
       override a similar rule in reveal.js */
    ul.task-list[class]{list-style: none;}
    ul.task-list li input[type="checkbox"] {
      font-size: inherit;
      width: 0.8em;
      margin: 0 0.8em 0.2em -1.6em;
      vertical-align: middle;
    }
    .display.math{display: block; text-align: center; margin: 0.5rem auto;}
  </style>
</head>
<body>
<h1 id="hydreight-technologies-inc.-tsxv-nurs-otcqb-hydtf">Hydreight
Technologies Inc. (TSXV: NURS | OTCQB: HYDTF)</h1>
<h2 id="business-summary">Business summary</h2>
<ul>
<li>Digital health platform enabling mobile, at-home healthcare and
wellness services via an integrated telemedicine, EMR, booking, and
payments stack across all 50 U.S. states.</li>
<li>Vertically integrated medical network with 3,000+ nurses, 200+
independent doctors, and a 503B pharmacy network; three revenue streams:
business partner contracts, commissions on app services, and pharmacy
sales (plus white-label solutions).</li>
<li>White-label and D2C enablement (VSDHOne) lets brands/franchises
launch compliant virtual-care offerings rapidly (GLP-1s, TRT, peptides,
genetic testing, etc.).</li>
<li>Asset-light model: collects cash in advance, no inventory carried;
platform tools for accounting, documentation, sales, inventory, booking,
and patient data management.</li>
</ul>
<h2 id="recent-developments">Recent developments</h2>
<ul>
<li>Closed $5.41M gross ($4.80M net) private placement (Feb 26, 2025)
with 3-year $2.00 warrants; added 3.49M warrants and 209.5k broker
warrants.</li>
<li>Q2 2025 launch/expansions: partnership with endocrinologist
Dr. Franklin Joseph (weight loss brand), added Liraglutide to GLP-1
suite, launched personalized genetic testing on VSDHOne.</li>
<li>LOI to acquire initial 5% of Perfect Scripts and partner to start a
503B pharmacy; Hydreight gets lowest pricing and rights up to 40%
ownership (Jul 14, 2025).</li>
<li>Announced up to $10M unsecured convertible debenture offering (9%
coupon, 36-month term, $4.06 conversion; Aug 18, 2025).</li>
<li>Awards: TSX Venture 50 (2025), Deloitte Technology Fast 500 (2024),
FT Americas’ Fastest Growing Companies 2025 (#13).</li>
</ul>
<h2 id="key-issues">Key issues</h2>
<ul>
<li>Revenue mix shift toward pharmacy sales (lower margin) compresses
gross margin percentage despite growth.</li>
<li>U.S. state sales tax complexity; provisions recorded and filings
subject to audit/reassessment.</li>
<li>Regulatory risk across 50 states; dependence on compliant physician
coverage and pharmacy partners.</li>
<li>Liquidity and dilution: planned convertible debentures (9% interest)
and equity plan increase (proposed to 9.0M shares) may add leverage and
dilution.</li>
<li>Related-party dependencies (VST services/loans) and concentration of
cash in two banks; non-audited interim financials.</li>
</ul>
<h2 id="financial-summary-cad-000s-unless-noted">Financial summary (CAD
‘000s, unless noted)</h2>
<table style="width:100%;">
<colgroup>
<col style="width: 42%" />
<col style="width: 7%" />
<col style="width: 7%" />
<col style="width: 7%" />
<col style="width: 7%" />
<col style="width: 7%" />
<col style="width: 7%" />
<col style="width: 7%" />
<col style="width: 7%" />
</colgroup>
<thead>
<tr>
<th>Metric (CAD ‘000s)</th>
<th style="text-align: right;">Q2 2025</th>
<th style="text-align: right;">Q2 2024</th>
<th style="text-align: right;">6M 2025</th>
<th style="text-align: right;">6M 2024</th>
<th style="text-align: right;">Q4 2024</th>
<th style="text-align: right;">Q4 2023</th>
<th style="text-align: right;">FY 2024</th>
<th style="text-align: right;">FY 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue</td>
<td style="text-align: right;">5,377</td>
<td style="text-align: right;">4,100</td>
<td style="text-align: right;">9,917</td>
<td style="text-align: right;">7,478</td>
<td style="text-align: right;">4,041</td>
<td style="text-align: right;">3,373</td>
<td style="text-align: right;">16,045</td>
<td style="text-align: right;">11,509</td>
</tr>
<tr>
<td>Gross Profit</td>
<td style="text-align: right;">1,930</td>
<td style="text-align: right;">1,560</td>
<td style="text-align: right;">3,435</td>
<td style="text-align: right;">2,791</td>
<td style="text-align: right;">1,372</td>
<td style="text-align: right;">1,570</td>
<td style="text-align: right;">5,696</td>
<td style="text-align: right;">4,961</td>
</tr>
<tr>
<td>Operating Income (EBIT)</td>
<td style="text-align: right;">11</td>
<td style="text-align: right;">(47)</td>
<td style="text-align: right;">(62)</td>
<td style="text-align: right;">(363)</td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">(874)</td>
<td style="text-align: right;">(441)</td>
<td style="text-align: right;">(1,935)</td>
</tr>
<tr>
<td>EBITDA</td>
<td style="text-align: right;">118</td>
<td style="text-align: right;">(22)</td>
<td style="text-align: right;">146</td>
<td style="text-align: right;">(292)</td>
<td style="text-align: right;">71</td>
<td style="text-align: right;">(805)</td>
<td style="text-align: right;">(260)</td>
<td style="text-align: right;">(1,826)</td>
</tr>
<tr>
<td>Adjusted EBITDA (reported)</td>
<td style="text-align: right;">182</td>
<td style="text-align: right;">218</td>
<td style="text-align: right;">345</td>
<td style="text-align: right;">172</td>
<td style="text-align: right;">270</td>
<td style="text-align: right;">(579)</td>
<td style="text-align: right;">490</td>
<td style="text-align: right;">(1,384)</td>
</tr>
<tr>
<td>Finance costs / Interest expense</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Net Income (Loss)</td>
<td style="text-align: right;">50</td>
<td style="text-align: right;">(27)</td>
<td style="text-align: right;">71</td>
<td style="text-align: right;">(336)</td>
<td style="text-align: right;">21</td>
<td style="text-align: right;">(899)</td>
<td style="text-align: right;">(405)</td>
<td style="text-align: right;">(1,937)</td>
</tr>
<tr>
<td>Cash generated from operating activities</td>
<td style="text-align: right;">n/a</td>
<td style="text-align: right;">n/a</td>
<td style="text-align: right;">569</td>
<td style="text-align: right;">287</td>
<td style="text-align: right;">n/a</td>
<td style="text-align: right;">n/a</td>
<td style="text-align: right;">857</td>
<td style="text-align: right;">(402)</td>
</tr>
<tr>
<td>Capital expenditures (PPE + intangibles)</td>
<td style="text-align: right;">n/a</td>
<td style="text-align: right;">n/a</td>
<td style="text-align: right;">717</td>
<td style="text-align: right;">480</td>
<td style="text-align: right;">n/a</td>
<td style="text-align: right;">n/a</td>
<td style="text-align: right;">1,182</td>
<td style="text-align: right;">211</td>
</tr>
<tr>
<td>Free Cash Flow (approx.)</td>
<td style="text-align: right;">n/a</td>
<td style="text-align: right;">n/a</td>
<td style="text-align: right;">(148)</td>
<td style="text-align: right;">(193)</td>
<td style="text-align: right;">n/a</td>
<td style="text-align: right;">n/a</td>
<td style="text-align: right;">(326)</td>
<td style="text-align: right;">(614)</td>
</tr>
<tr>
<td>Adjusted Revenue (non-GAAP)</td>
<td style="text-align: right;">7,350</td>
<td style="text-align: right;">5,590</td>
<td style="text-align: right;">13,880</td>
<td style="text-align: right;">10,460</td>
<td style="text-align: right;">5,743</td>
<td style="text-align: right;">4,992</td>
<td style="text-align: right;">22,321</td>
<td style="text-align: right;">17,050</td>
</tr>
<tr>
<td>Adjusted Gross Margin (non-GAAP)</td>
<td style="text-align: right;">2,130</td>
<td style="text-align: right;">1,370</td>
<td style="text-align: right;">4,090</td>
<td style="text-align: right;">2,490</td>
<td style="text-align: right;">1,679</td>
<td style="text-align: right;">1,779</td>
<td style="text-align: right;">5,750</td>
<td style="text-align: right;">5,341</td>
</tr>
<tr>
<td>Gross Margin (%)</td>
<td style="text-align: right;">35.9%</td>
<td style="text-align: right;">38.0%</td>
<td style="text-align: right;">34.6%</td>
<td style="text-align: right;">37.3%</td>
<td style="text-align: right;">34.0%</td>
<td style="text-align: right;">46.5%</td>
<td style="text-align: right;">35.5%</td>
<td style="text-align: right;">43.1%</td>
</tr>
<tr>
<td>New business partner signups (count)</td>
<td style="text-align: right;">219</td>
<td style="text-align: right;">~124¹</td>
<td style="text-align: right;">395</td>
<td style="text-align: right;">~231¹</td>
<td style="text-align: right;">n/a</td>
<td style="text-align: right;">n/a</td>
<td style="text-align: right;">n/a</td>
<td style="text-align: right;">n/a</td>
</tr>
<tr>
<td>Cash (end of period)</td>
<td style="text-align: right;">6,104</td>
<td style="text-align: right;">1,402</td>
<td style="text-align: right;">6,104</td>
<td style="text-align: right;">1,402</td>
<td style="text-align: right;">1,187</td>
<td style="text-align: right;">1,784</td>
<td style="text-align: right;">1,187</td>
<td style="text-align: right;">1,784</td>
</tr>
</tbody>
</table>
<p>Notes:</p>
<ul>
<li>Source: Company MD&amp;A and unaudited interim financial statements
for the three and six months ended June 30, 2025 (CAD), plus audited FY
2024 and FY 2023 and MD&amp;A quarterly disclosures.</li>
<li>Operating income (EBIT) = Gross Profit − Total Operating Expenses.
Q4’24: 1,371.951 − 1,363.758 ≈ 8; Q4’23: 1,569.974 − 2,443.862 ≈ −874.
FY’24: 5,696.253 − 6,137.434 ≈ −441; FY’23: 4,961.450 − 6,896.054 ≈
−1,935.</li>
<li>EBITDA = EBIT + Amortization &amp; Depreciation. Q4’24: 8 + 62.853 ≈
71; Q4’23: −874 + 68.661 ≈ −805; FY’24: −441 + 181.136 ≈ −260; FY’23:
−1,935 + 108.389 ≈ −1,826.</li>
<li>Adjusted EBITDA (non-GAAP) per company: Q4’24 $270k; Q4’23 $(579)k;
FY’24 $490k; FY’23 $(1,384)k.</li>
<li>Cash from operating activities (FY): 2024 $856.9k; 2023 $(402.2)k.
Capex approximated as additions to intangible assets + additions to
property &amp; equipment: FY’24 ≈ $1,182.4k + $0.0k = $1,182.4k; FY’23 ≈
$208.6k + $2.9k = $211.5k. Free Cash Flow (approx.) = CFO − Capex.</li>
<li>Adjusted Revenue and Adjusted Gross Margin (non-GAAP) per company:
Q4’24 $5,742.5k / $1,679.2k; Q4’23 $4,992.2k / $1,779.2k; FY’24
$22,321.3k / $5,749.8k; FY’23 $17,050.3k / $5,340.8k.</li>
<li>Gross Margin % (GAAP) per MD&amp;A: Q4’24 33.95%; Q4’23 46.54%;
FY’24 35.50%; FY’23 43.11%. Rounded to one decimal in table.</li>
<li>¹ New partner signups (comparatives) approximated from growth
disclosures: Q2’24 ≈ 219 / 1.77 ≈ 124; 6M’24 ≈ 395 / 1.71 ≈ 231. Marked
as approximate.</li>
<li>Quarterly CFO/Capex not disclosed (n/a). All figures rounded to
nearest $1,000; percentages to one decimal.</li>
</ul>
<h2 id="capitalization-cash-debt-and-enterprise-value">Capitalization,
Cash, Debt, and Enterprise Value</h2>
<table>
<colgroup>
<col style="width: 44%" />
<col style="width: 55%" />
</colgroup>
<thead>
<tr>
<th>Item</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stock Price</td>
<td>$4.38 (CAD)</td>
</tr>
<tr>
<td>Basic Shares (pro forma Aug 25, 2025)</td>
<td>46,566,356</td>
</tr>
<tr>
<td>Fully Diluted Shares (pro forma)</td>
<td>49,829,571</td>
</tr>
<tr>
<td>Implied Market Cap (Basic)</td>
<td>$204.0m</td>
</tr>
<tr>
<td>Implied Market Cap (Fully Diluted)</td>
<td>$218.3m</td>
</tr>
<tr>
<td>Cash (Jun 30, 2025)</td>
<td>$6.10m</td>
</tr>
<tr>
<td>Cash (pro forma incl. post-Q2 warrant exercises)</td>
<td>$7.83m</td>
</tr>
<tr>
<td>Debt (interest-bearing)</td>
<td>$0.0m</td>
</tr>
<tr>
<td>Related party payable (long-term, non-interest)</td>
<td>$0.75m</td>
</tr>
<tr>
<td>EV (Basic, using interest-bearing debt only)</td>
<td>$196.1m</td>
</tr>
<tr>
<td>EV (Fully Diluted, using interest-bearing debt only)</td>
<td>$204.8m</td>
</tr>
<tr>
<td>EV (Basic, incl. related-party payable as debt-like)</td>
<td>$196.9m</td>
</tr>
<tr>
<td>EV (Fully Diluted, incl. related-party payable as debt-like)</td>
<td>$205.6m</td>
</tr>
</tbody>
</table>
<p>Notes:</p>
<ul>
<li>Share counts
<ul>
<li>Basic at June 30, 2025: 45,210,358.</li>
<li>Post-Q2 issuances per Subsequent Events: 721,300 purchase warrants
exercised at $2.00, 184,698 broker warrants exercised at $1.55, and
450,000 RSUs settled into shares. Total adds 905,998 + 450,000 =
1,355,998 shares.</li>
<li>Basic pro forma (as disclosed in MD&amp;A, Aug 25, 2025): 46,566,356
= 45,210,358 + 1,355,998.</li>
<li>Outstanding dilutives after the above exercises: 2,771,000 purchase
warrants (at $2.00), 24,840 broker warrants (at $1.55), and 467,375 RSUs
outstanding. Fully diluted shares = 46,566,356 + 2,771,000 + 24,840 +
467,375 = 49,829,571.</li>
</ul></li>
<li>Cash
<ul>
<li>Reported cash (Jun 30, 2025): $6,104,118.</li>
<li>Post-Q2 warrant exercise proceeds (per Subsequent Events):
$1,442,600 (721,300 × $2.00) + $286,282 (184,698 × $1.55) =
$1,728,882.</li>
<li>Pro forma cash = $6,104,118 + $1,728,882 = $7,833,000.</li>
<li>For fully diluted EV (assuming remaining warrants also exercised),
add incremental proceeds: (2,771,000 × $2.00) + (24,840 × $1.55) =
$5,580,502; FD cash = $7,833,000 + $5,580,502 = $13,413,502.</li>
</ul></li>
<li>Debt
<ul>
<li>Interest-bearing debt: none reported at June 30, 2025 (convertible
debentures were announced Aug 18, 2025 but not closed as of the MD&amp;A
date).</li>
<li>Related-party payable to parent (non-interest, long-term by waiver):
$749,879; shown separately and included in “alternative” EV for a
debt-like view.</li>
</ul></li>
<li>Market capitalization and EV
<ul>
<li>Market cap (Basic) = 46,566,356 × $4.38 ≈ $203.96m (shown as
$204.0m).</li>
<li>Market cap (Fully Diluted) = 49,829,571 × $4.38 ≈ $218.25m (shown as
$218.3m).</li>
<li>EV (Basic; interest-bearing debt only) = Market cap − Pro forma cash
+ Debt = $203.96m − $7.83m + $0.00m ≈ $196.13m (shown as $196.1m).</li>
<li>EV (FD; interest-bearing debt only) = $218.25m − $13.41m + $0.00m ≈
$204.84m (shown as $204.8m).</li>
<li>EV including related-party payable adds ~$0.75m to each EV
figure.</li>
</ul></li>
<li>Pro forma considerations not included in EV/share count:
<ul>
<li>Convertible debenture offering (up to $10m, 9% coupon, $4.06
conversion) announced Aug 18, 2025 was not closed as of the MD&amp;A
date; therefore no debt, cash, or additional potential shares from
conversion/agents’ warrants are included in the above figures.</li>
</ul></li>
<li>All figures in CAD, rounded to one decimal million where
applicable.</li>
</ul>
<h2 id="valuation">Valuation</h2>
<table>
<thead>
<tr>
<th>Metric</th>
<th>Basic</th>
<th>Fully Diluted</th>
</tr>
</thead>
<tbody>
<tr>
<td>EV/EBIT (LTM)</td>
<td>n/m</td>
<td>n/m</td>
</tr>
<tr>
<td>EV/adjusted EBITDA (LTM)</td>
<td>295.8x</td>
<td>308.8x</td>
</tr>
<tr>
<td>EV/unlevered FCF (LTM)</td>
<td>n/m</td>
<td>n/m</td>
</tr>
</tbody>
</table>
<p>Notes:</p>
<ul>
<li>LTM period is defined as Jul 1, 2024 to Jun 30, 2025. Computation
uses FY 2024 + 6M 2025 − 6M 2024 for each metric to avoid double
counting.</li>
<li>EBIT (LTM, CAD ‘000): = FY’24 (−441) + 6M’25 (−62) − 6M’24 (−363) =
−140.</li>
<li>Adjusted EBITDA (LTM, CAD ‘000): = FY’24 490 + 6M’25 345 − 6M’24 172
= 663.</li>
<li>Unlevered Free Cash Flow (LTM, CAD ‘000): FCF LTM = FY’24 (−326) +
6M’25 (−148) − 6M’24 (−193) = −281. Finance costs/interest expense are
$0; therefore, unlevered FCF = FCF.</li>
<li>EV used is from the “Capitalization, Cash, Debt, and Enterprise
Value” section (pro forma as of Aug 25, 2025): Basic EV = $196.1m; Fully
Diluted EV = $204.8m.</li>
<li>EV/Adjusted EBITDA (Basic) = 196.1 / 0.663 ≈ 295.8x; EV/Adjusted
EBITDA (FD) = 204.8 / 0.663 ≈ 308.8x.</li>
<li>Negative denominators produce “n/m” (not meaningful).</li>
</ul>
</body>
</html>
